A method for preparing amino alcohols by asymmetric hydrogenation and its application
Through asymmetric hydrogenation reaction and removal of amino protecting groups, the problem of efficient synthesis of chiral pyrrolidine and piperidine compounds was successfully solved, and efficient, stable and low-cost production was achieved, meeting industrial needs.
Patent Information
- Application Number
- CN202111328540.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-11-10
AI Technical Summary
The prior art has problems of high cost and insufficient practicality in the asymmetric synthesis of chiral pyrrolidine, and there is a lack of simple and efficient method for large-scale production.
Using asymmetric hydrogenation reaction method, transition metal catalysts such as ruthenium, rhodium, iridium, palladium, etc. are combined with chiral ligands to form chiral amino alcohol intermediates through catalytic hydrogenation reaction, and remove amino protecting groups and nucleophilic rings. The reaction yields optically pure chiral pyrrolidine and piperidine compounds.
The synthesis of chiral pyrrolidine and piperidine compounds with high efficiency, stability and low cost has achieved enantioselectivity and high conversion rate of 99%, and has industrial application value.
Smart Images

Figure CN116102464B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chemical catalytic reactions, and specifically relates to a method for preparing amino alcohols by asymmetric hydrogenation and application thereof. Background Art
[0002] Chiral pyrrolidine compounds are widely present in biologically active molecules, drugs, and natural product fragments, such as the drug Larotrectinib sulfate, which was launched in 2018, and can be used to treat adult and pediatric patients with locally advanced or metastatic solid tumors carrying NTRK gene fusions; the drug Osilodrostat, which was launched in 2020 and is the first FDA-approved human 11-β-hydroxylase inhibitor that can directly block the synthesis of adrenal cortisol and is an orphan drug for the treatment of hypercortisolism; and the natural product nicotine.
[0003]
[0004] Since chiral pyrrolidine and piperidine compounds have great industrial value in the pharmaceutical field, people have conducted in-depth research on their synthesis methods and developed many synthetic routes. At present, there are many methods for obtaining chiral pyrrolidine, but these methods still have certain limitations, especially high cost and practicality still need to be improved, and there is no simple and efficient method that can be widely used in the asymmetric synthesis of chiral pyrrolidine. Therefore, it is of great significance to realize the large-scale production of chiral pyrrolidine by means of asymmetric catalytic preparation technology. Summary of the invention
[0005] The present invention discloses a method for preparing amino alcohol by asymmetric hydrogenation and its application. The chemical reaction equation is as follows:
[0006]
[0007] Among them, R of the chemical formula (I) and (II) 1 represents a C1-C12 alkyl group, an aryl group, or an alkyl group or an aryl group substituted with a heteroatom, R 2 represents an amino protecting group, n represents a saturated straight or branched chain group containing 1 to 5 carbon atoms, and the * represents two configurations, R or S; the transition metal catalyst used is prepared by mixing a metal salt and a chiral ligand, the catalyst metal salt is selected from common transition metal compounds such as ruthenium, rhodium, iridium, palladium, etc., and the chiral ligand is selected from:
[0008]
[0009] As a preferred embodiment of the present invention, R of the chemical formula (I) and (II) 2represents an amino protecting group selected from benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methoxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), methyl (or ethyl or isopropyl)oxycarbonyl (COOMe, COOEt, COO i 1-(4-nitrophenyl)-2-yl (Pr), 1-(2-phthaloyl)-4-yl (Pht), 1-toluenesulfonyl (Ts), 1-trifluoroacetyl (Tfa), 1-nitrobenzenesulfonyl (Ns), 1-pivaloyl, 1-benzoyl, 1-trityl (Trt), 2,4-dimethoxybenzyl (Dmb), 1-methoxybenzyl (PMB), 1-benzyl (Bn), etc.
[0010] As a preferred embodiment of the present invention, the solvent used for asymmetric hydrogenation is methanol, ethanol, isopropanol, tetrahydrofuran, dichloromethane, ethyl acetate, n-hexane, dichloromethane, 1,2-dichloroethane, toluene, xylene, 1,4-dioxane, methyl tert-butyl ether or a mixture in any proportion.
[0011] As a preferred embodiment of the present invention, the base used for asymmetric hydrogenation is potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, potassium methoxide or a mixture in any proportion.
[0012] As a preferred embodiment of the present invention, the molar ratio of the intermediate (I) to the catalyst is 5 mmol: 0.01-1 nmol.
[0013] As a preferred embodiment of the present invention, the reaction temperature of asymmetric hydrogenation is 20-80 degrees Celsius.
[0014] As a preferred embodiment of the present invention, the pressure of asymmetric hydrogenation is 1-10 MPa.
[0015] As a preferred embodiment of the present invention, the transition metal catalyst is preferably [Ir(COD)Cl] 2 , the chiral ligand is preferably:
[0016] and its enantiomer L10.
[0017] The present invention also discloses an asymmetric synthesis method of chiral pyrrolidine and piperidine compounds, and the synthesis route thereof is as follows:
[0018]
[0019] Wherein, when n in compounds (I) and (II) is 3 or 4, the chiral amino alcohol compound (II) is prepared by the above-mentioned asymmetric catalytic hydrogenation method.
[0020] Furthermore, the following technical solutions can be used to achieve this, including:
[0021] The alcoholic hydroxyl group of the chiral amino alcohol compound (II) reacts with a suitable reagent to be converted into X to obtain an intermediate (III), wherein X is selected from common leaving groups such as halogen, sulfonate, phosphate, including chlorine, bromine, iodine, methanesulfonate (OMs), trifluoromethanesulfonate (OTf), p-toluenesulfonate (OTs), nitrosulfonate (ONs), etc.
[0022] Under appropriate conditions, the intermediate (III) reacts with a suitable reagent to remove the amino protecting group R 2 , R 2 In the case of tert-butyloxycarbonyl (Boc), the reagent for removing the amino protecting group is hydrochloric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, etc., preferably trifluoroacetic acid, methanesulfonic acid, etc.
[0023] The intermediates without the protective group are subjected to intramolecular nucleophilic ring-closing reaction under alkaline conditions without separation and purification, thereby obtaining optically pure chiral pyrrolidine and piperidine compounds. It is particularly noted that this method can be applied to the asymmetric synthesis of nicotine and larotrectinib intermediates, and the synthetic route is as follows:
[0024]
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] (1) The present invention has successfully developed a method for synthesizing chiral pyrrolidine, wherein compound (I) undergoes a catalytic hydrogenation reaction under the action of a chiral ligand to efficiently obtain a chiral alcohol intermediate (II). The reaction has high stability and reactivity, achieves excellent stereo control, and can obtain a chiral alcohol intermediate with an enantioselectivity of greater than 99%.
[0027] (2) Through a large number of experimental studies, it was found that the preferred catalyst system [Ir(COD)Cl] 2 / f-phamidol, asymmetric hydrogenation reaction has very high reactivity, the catalyst turnover number (TON, turnover number) is as high as 500000.
[0028] (3) The present invention has stable operation, low cost, and environmental friendliness, and has extremely high industrial value. DETAILED DESCRIPTION
[0029] The following further discloses some non-limiting examples to further illustrate the present invention, but the present invention is not limited thereto. Experimental methods without specific conditions in the examples are usually carried out according to conventional conditions and conditions described in the manual, or according to conditions recommended by the manufacturer; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial channels.
[0030] Example 1: In compound (I), R 1 is phenyl, R 2 It is tert-butyloxycarbonyl (Boc).
[0031]
[0032] Under argon atmosphere, [Ir(COD)Cl] 2 (3.4mg, 0.005mol) and chiral ligand (S,S,R)-f-phamidol-L3 (6.0mg, 0.0105mmol) were dissolved in 5mL isopropanol and stirred at room temperature for 3 hours to obtain an orange clear solution. 10uL of the orange solution was taken with a microsyringe and added to a mixed system of intermediate (II-a) (52.6mg, 0.2mmol), isopropanol (1mL) and potassium tert-butoxide (1.1mg, 0.01mmol). The reaction system was placed in an autoclave, the gas in the autoclave was replaced with hydrogen three times, and finally filled with 50atm hydrogen, and reacted at 25°C for 2 hours. After the reaction was completed, the gas in the autoclave was slowly released, 50mL of dichloromethane was added, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 53mg of a colorless oily liquid, i.e., the hydrogenation product (II-a), with a yield of 99%. The ee value was 99% as measured by HPLC analysis.
[0033] Embodiment 2-10
[0034]
[0035] The present invention is to investigate the effect of the type of catalyst used in asymmetric hydrogenation on the conversion rate (conv.) and enantiomeric selectivity (ee). Based on Example 1, the catalyst ligand L3 is replaced by L1, L2, L4, L5, L6, L7, L8, L9, and L10 in sequence.
[0036] The effects of different catalysts on the conversion rate and ee value of the reduction of compound (Ia) in Examples 1-10 are shown in Table 1 below; wherein the conversion rate (conv.) and enantiomeric selectivity (ee) were measured by HPLC.
[0037] Table 1
[0038]
[0039]
[0040] Examples 11-18
[0041]
[0042] In order to investigate the effect of the reaction system solvent on the reaction, based on Example 1, the solvent was replaced with MeOH, EtOH, EtOAc, DCM, THF, Hexane and Toluene, etc. The reaction time was 2h, S / C=10000, and the effects of different solvents on the conversion rate and ee value of the reduction of compound (Ia) are shown in Table 2 below. It is worth mentioning that in isopropanol, when the chiral ligand used is its enantiomer (R,R,S)-f-phamidol-L3, the product II-a of the opposite configuration can be obtained with good stereoselectivity. This result can facilitate us to select the catalyst of the corresponding configuration according to the chirality of the substrate in practical applications. Among them, the conversion rate (conv.) and enantiomeric selectivity (ee) are measured by HPLC.
[0043] Table 2
[0044] serial number catalyst Reaction solvent conv.(%) ee(%) Example 1 (S,S,R)-f-phamidol-L3 <![CDATA[ i PrOH]]> >99 >99 Embodiment 11 (S,S,R)-f-phamidol-L3 MeOH NR - Example 12 (S,S,R)-f-phamidol-L3 EtOH 21 >99 Example 13 (S,S,R)-f-phamidol-L3 EtOAc 40 >99 Embodiment 14 (S,S,R)-f-phamidol-L3 DCM >99 >99 Embodiment 15 (S,S,R)-f-phamidol-L3 THF 8 >99 Example 16 (S,S,R)-f-phamidol-L3 Hexane 74 >99 Embodiment 17 (S,S,R)-f-phamidol-L3 Toluene 99 >99 Embodiment 18 (S,S,R)-f-phamidol-L3 DCE 97 >99
[0045] Examples 19-26
[0046]
[0047] In order to investigate the effect of the base added to the reaction system on the reaction, isopropanol was used as the solvent, and on the basis of Example 1, potassium tert-butoxide was replaced with potassium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, potassium methoxide, sodium tert-butoxide, potassium tert-butoxide, and lithium tert-butoxide in sequence. The reaction time was 2h, S / C=10000, and the following Examples 19-26 were carried out. The synthesis routes are shown below, and the results are shown in Table 3 below.
[0048] Table 3
[0049] serial number Alkali Reaction solvent conv.(%) ee(%) Example 1 <![CDATA[ t Full]]> <![CDATA[ i PrOH]]> >99 >99 Embodiment 19 <![CDATA[K 2 CO 3 ]]> <![CDATA[ i PrOH]]> 92 >99 Embodiment 20 <![CDATA[Cs 2 CO 3 ]]> <![CDATA[ i PrOH]]> >99 >99 Embodiment 21 KOH <![CDATA[ i PrOH]]> >99 >99 Embodiment 22 NaOH <![CDATA[ i PrOH]]> >99 >99 Embodiment 23 NeA <![CDATA[ i PrOH]]> >99 >99 Embodiment 24 KOMe <![CDATA[ i PrOH]]> >99 >99 Embodiment 25 <![CDATA[ t Good]]> <![CDATA[ i PrOH]]> >99 >99 Embodiment 26 <![CDATA[ t BuOLi]]> <![CDATA[ i PrOH]]> >99 >99
[0050] Examples 27-30
[0051]
[0052] Furthermore, using the catalyst (S,S,R)-f-phamidol-L3 as the catalyst and the green solvent isopropanol as the solvent, the amount of catalyst, the reaction time, etc. were changed respectively, and the results are shown in Table 4 below.
[0053] Table 4
[0054]
[0055]
[0056] Embodiment 31
[0057]
[0058] Furthermore, in order to investigate the universality of the reaction for different substrates, the catalyst (S,S,R)-f-phamidol-L3 was used as a catalyst, potassium methoxide as a base, and green solvent isopropanol as a solvent. The reaction temperature was 25 degrees Celsius, the gas pressure was 50 bar, the reaction time was 4 h, and S / C was 10000. Asymmetric catalytic hydrogenation experiments were carried out on different substrates, and the results of the products are shown in Table 5 below.
[0059] Table 5 Expansion of substrates for asymmetric hydrogenation of aminoketones
[0060]
[0061]
[0062] Example 32 (enlarged, S / C=500000)
[0063]
[0064] Under argon atmosphere, [Ir(COD)Cl] 2 (1.4 mg, 0.002 mol) and chiral ligand (S,S,R)-f-phamidol-L3 (2.4 mg, 0.0042 mmol) were dissolved in 10 mL of isopropanol and stirred at room temperature for 2 hours to obtain an orange clear solution. 20 uL of the orange solution was taken with a microsyringe and added to a mixed system of intermediate (Ia) (1.05 g, 4 mmol), isopropanol (2 mL) and potassium methoxide (14 mg, 0.2 mmol). The reaction system was placed in an autoclave, and the gas in the autoclave was replaced with hydrogen three times. Finally, 50 atm of hydrogen was filled and reacted at 25 ° C for 16 hours. After the reaction was completed, the gas in the autoclave was slowly released, the alkali was filtered off with silica gel, rinsed with DCM, and concentrated under reduced pressure to obtain 1.05 g of white solid, i.e., hydrogenation product (II-a), with a yield of 99%. The ee value was measured to be >99% by HPLC analysis. [α] D 25 = +22.1 (c = 1.00 in CHCl 3).Theenantiomeric excess was determined by HPLC on Chiralcel IA column,210nm,30℃,n-hexane:i-PrOH=92:8; flow rate 1.0mL / min; t R (minor)=15.0min,t R (major) = 19.1min. 1 H NMR (600 MHz, CDCl 3 )δ7.26–7.26(m,4H),7.18–7.17(m,1H),4.60–4.35(m,2H),3.05–3.05(m,2H),2.40(br,1H ),1.73–1.67(m,1H),1.65–1.60(m,1H),1.51–1.49(m,1H),1.44–1.42(m,1H),1.34(s,9H). 13 C NMR (151 MHz, CDCl 3 )δ156.07,144.69,128.37,127.43,125.75,79.10,74.00,40.24,35.98,28.35,26.39.
[0065] Embodiment 33
[0066]
[0067] Weigh 1.06g of chiral alcohol intermediate (II-a, 4mmol), add 20mL of dichloromethane to dissolve, then drop 0.84mL of triethylamine (6mmol), place the reaction system in a 0℃ low temperature cold bath, slowly drop 0.40mL of methanesulfonyl chloride (5.2mmol) while stirring, continue to react at 0℃ for 3h after the dropwise addition, add 80mL of ethyl acetate to dilute, wash twice with water, wash twice with saturated sodium bicarbonate, dry the organic phase with anhydrous sodium sulfate, and concentrate to obtain a yellow oily liquid. Then drop 1.04mL of methanesulfonic acid (16mmol) and 16mL of dichloromethane into the yellow oily liquid obtained above, stir at room temperature for 2h, place the reaction solution in a 0℃ low temperature cold bath after the reaction, then add 20mL of water, and drop sodium hydroxide solution (1M) while stirring until the pH is about 11. The reaction mixture was extracted three times with 150 mL of dichloromethane, the organic phase was retained, dried with anhydrous sodium sulfate, the solvent was removed under reduced pressure, and 476 mg of colorless oily liquid (IV-a) was obtained after column purification. The reaction yield was 81%, and the ee value was 95% as determined by HPLC analysis. [α] D 25=-31.3(c=1.00in CHCl 3 ).The enantiomeric excess was determined by HPLC on Chiralcel OD-3column,254nm,30℃,n-hexane(0.1%DEA):i-PrOH=95:5; flow rate 1.0mL / min; t R (minor)=5.8min,t R (major) = 6.6min. 1 H NMR (600 MHz, CDCl 3 )δ7.36(d,J=7.5Hz,2H),7.32(t,J=7.6Hz,2H),7.23(t,J=7.2Hz,1H),4.12(t,J=7.8Hz,1H),3 .22–3.18(M,1H),3.03–2.97(M,2H),2.22–2.17(M,1H),1.97–1.82(m,2H),1.73–1.66(M,1H). 13 C NMR (151 MHz, CDCl 3 )δ144.25,128.27,126.77,126.47,62.47,46.75,34.11,25.42.
[0068] Embodiment 34
[0069]
[0070] Weigh 1.06g of chiral alcohol intermediate (II-b, 4mmol), add 20mL of dichloromethane to dissolve, then drop 0.84mL of triethylamine (6mmol), place the reaction system in a 0℃ low temperature cold bath, slowly drop 0.40mL of methanesulfonyl chloride (5.2mmol) while stirring, continue to react at 0℃ for 3h after the dropwise addition, add 80mL of ethyl acetate to dilute, wash twice with water, wash twice with saturated sodium bicarbonate, dry the organic phase with anhydrous sodium sulfate, and concentrate to obtain a yellow oily liquid. Then drop 1.04mL of methanesulfonic acid (16mmol) and 16mL of dichloromethane into the yellow oily liquid obtained above, stir at room temperature for 2h, place the reaction solution in a 0℃ low temperature cold bath after the reaction, then add 20mL of water, and drop sodium hydroxide solution (1M) while stirring until the pH is about 11. The reaction mixture was extracted three times with 150 mL of dichloromethane, the organic phase was retained, dried with anhydrous sodium sulfate, the solvent was removed under reduced pressure, and 476 mg of colorless oily liquid (IV-b) was obtained after column purification. The reaction yield was 80%. The ee value was >99% as determined by HPLC analysis. [α]D 25 =-30.6 (c = 0.25, MeOH), 1 H NMR (400 MHz, CDCl 3 )δ:8.60(d,J=2.0Hz,1H),8.49(dd,J=1.6,4.8Hz 1H),7.71-7.73(m,1H),7.25-7.28(m,1H),4.19(t,J=7.6Hz,1H),3.21-3.22( m,1H),3.07-3.11(m,1H),2.30-2.40(m,2H),1.87-2.04(m,2H),1.66(m,1H). 13 C NMR (101 MHz, CDCl 3 )δ:148.5,148.1,140.0,134.0,123.2,59.9,46.8,34.2,25.4.
[0071] Example 35 Synthesis of Nicotine
[0072]
[0073] Intermediate IV-b (1.48 g, 10 mmol) was added to a mixed solution of 18 mL 88% formic acid and 9.2 mL 37% formaldehyde. The mixture was reacted at 80°C for 5 h, then cooled to room temperature, solid potassium carbonate was added until the reaction solution was alkaline (pH = 10-11), extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, spin-dried, and distilled under reduced pressure to obtain 1.3 g of the target product nicotine. Nicotine, colorless to light yellow oily liquid, 82% yield, 99% ee, [α] 25 D =-98.2(c=1,CHCl 3 ), 1 HNMR (400MHz, CDCl 3 ): δ8.56-8.47(m,2H),7.75-7.67(m,1H),7.27-7.23(m,1H),3.32-3.21(m,1H),3.10(t,J=8.3Hz,1H),2. 39-2.28(m,1H),2.28-2.19(m,1H),2.17(s,3H),2.04-1.91(m,1H),1.89-1.79(m,1H),1.78-1.66(m,1H). 13 C NMR (101 MHz, CDCl 3): δ149.5,148.6,138.6,134.9,123.6,68.9,57.0,40.3,35.1,22.6.
[0074] Example 36 (enlarged, S / C=200000)
[0075]
[0076] Under argon atmosphere, [Ir(COD)Cl] 2 (1.4 mg, 0.002 mol) and chiral ligand (S,S,R)-f-phamidol-L3 (2.4 mg, 0.0042 mmol) were dissolved in 10 mL of isopropanol and stirred at room temperature for 2 hours to obtain an orange clear solution. 50 uL of the orange solution was taken with a microsyringe and added to a mixed system of intermediate (Ih) (1.12 g, 4 mmol), isopropanol (2 mL) and potassium methoxide (14 mg, 0.2 mmol). The reaction system was placed in an autoclave, and the gas in the autoclave was replaced with hydrogen three times. Finally, 50 atm of hydrogen was filled and reacted at 25 ° C for 16 hours. After the reaction was completed, the gas in the autoclave was slowly released, the alkali was filtered off with silica gel, rinsed with DCM, and concentrated under reduced pressure to obtain 1.13 g of colorless oily liquid, i.e., hydrogenation product (II-e), with a yield of 99%. The ee value was measured to be >99% by HPLC analysis. [α] D 25 = +22.2 (c = 1.00 in CHCl 3 ).The enantiomeric excess was determined by HPLC on Chiralcel IA column,210nm,30℃,n-hexane:i-PrOH=92:8; flow rate 1.0mL / min; t R (minor)=11.2min,t R (major) = 12.9min. 1 H NMR (600 MHz, CDCl 3 )δ7.29–7.27(m,2H),7.01–6.99(m,2H),4.69–4.66(m,2H),3.12–3.12(m,2H),2.98(br,1H ),1.78–1.72(m,1H),1.70–1.64(m,1H),1.59–1.56(m,1H),1.49–1.48(m,1H),1.41(s,9H). 13 C NMR (151 MHz, CDCl 3)δ162.01(d,J=245.1Hz),156.13,140.52,127.36(d,J=8.0Hz),115.09(d,J=21.3Hz),79.17,73.23,40.15,36.04,28.32,26.36. 19 F NMR (376 MHz, CDCl 3 )δ-115.26.
[0077] Embodiment 37
[0078]
[0079] Weigh 1.13g of chiral alcohol intermediate (II-h, 4mmol), add 20mL of dichloromethane to dissolve, then drop 0.84mL of triethylamine (6mmol), place the reaction system in a 0℃ low temperature cold bath, slowly drop 0.40mL of methanesulfonyl chloride (5.2mmol) while stirring, continue to react at 0℃ for 3h after the dropwise addition, add 80mL of ethyl acetate to dilute, wash twice with water, wash twice with saturated sodium bicarbonate, dry the organic phase with anhydrous sodium sulfate, and concentrate to obtain a yellow oily liquid. Then drop 1.04mL of methanesulfonic acid (16mmol) and 16mL of dichloromethane into the yellow oily liquid obtained above, stir at room temperature for 2h, place the reaction solution in a 0℃ low temperature cold bath after the reaction, then add 20mL of water, and drop sodium hydroxide solution (1M) while stirring until the pH is about 11. The reaction mixture was extracted three times with 150 mL of dichloromethane, the organic phase was retained, dried with anhydrous sodium sulfate, the solvent was removed under reduced pressure, and 561 mg of colorless oily liquid (IV-h) was obtained after column purification. The reaction yield was 85%, and the ee value was 99% as determined by HPLC analysis. [α] D 25 = -20.5 (c = 1.00 in CHCl 3 ), 1 H NMR (400 MHz, CDCl 3 )δ:7.29–7.26(m,2H),6.98–6.93(m,2H),4.07–4.03(m,1H),3.16–3.12(m,1H),2.97–2.92(m,1H),2.33(br,1H),2.15–2.08(m,1H),1.90–1.87(m,2H),1.63-1.55(m,1H). Its H NMR spectrum data are consistent with the literature (Org.Lett.2017,16,4215-4218.)
[0080] Embodiment 38
[0081]
[0082] Under argon atmosphere, [Ir(COD)Cl] 2 (1.4 mg, 0.002 mmol) and chiral ligand (R,R,S)-f-phamidol-L10 (2.4 mg, 0.0042 mmol) were dissolved in 10 mL of isopropanol and stirred at room temperature for 3 hours to obtain an orange clear solution. 2.5 mL of the orange solution was taken with a syringe and added to a mixed system of intermediate (II) (29.9 g, 100 mmol), isopropanol (50 mL) and potassium methoxide (70 mg, 1 mmol). The reaction system was placed in an autoclave, and the gas in the autoclave was replaced with hydrogen three times. Finally, 50 atm of hydrogen was filled and reacted at 25°C for 24 hours. After the reaction was completed, the gas in the autoclave was slowly released, the reaction solution was filtered with silica gel to remove the catalyst and alkali, and rinsed with DCM. The filtrate was concentrated under reduced pressure to obtain 29.5 g of white solid, i.e., hydrogenation product (III), with a yield of 98%. The ee value was >99% as determined by HPLC analysis. The enantiomers were determined by HPLC under the following chromatographic conditions: Chiralcel AD-3 column, 210 nm, 30°C, mobile phase: n-hexane:i-PrOH=90:10; flow rate 1.0 mL / min; t R (major)=10.5min,t R (minor) = 14.1min. Characterization data of compound II-1: [α] D 25 = -18.2 (c = 1.00 in CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 )δ7.20–7.16(m,1H),6.95–6.83(m,2H),4.98(q,J=5.7Hz,1H),4.71(br,1H),3.42 (s,1H),3.18–3.07(m,2H),1.72(q,J=7.3Hz,2H),1.65–1.50(m,2H),1.39(s,9H). 13 C NMR (151 MHz, CDCl 3)δ158.92(dd,J=242.0,1.9Hz),156.29,155.25(dd,J=240.6,2.1Hz),133.84(dd,J=15.6,6.3Hz),116.11(dd,J= 25.0, 8.5Hz), 114.75 (dd, J=24.2, 8.6Hz), 113.73 (dd, J=24.9, 5.0Hz), 79.33, 67.23, 40.12, 34.71, 28.30, 26.21. 19 F NMR (376 MHz, CDCl 3 )δ-118.46,-125.70.
[0083] Embodiment 39
[0084]
[0085] Weigh 12.0g of compound II-I (40mmol), add 40mL of dichloromethane to dissolve, then drop 11.2mL of triethylamine (80mmol), place the reaction system in a 0℃ low temperature cold bath, slowly drop 3.4mL of methanesulfonyl chloride (44mmol) while stirring, continue to react at 0℃ for 30min after the dropwise addition, wash with saturated sodium carbonate after the reaction, extract three times with 120mL of dichloromethane, and concentrate to obtain 14.4g of yellow oily liquid. Then drop 20mL of 30% sulfuric acid and 50mL of dichloromethane into the yellow oily liquid obtained above, stir at room temperature for 2h, concentrate the reaction solution after the reaction, then add 100mL of water to dissolve, place the reaction solution in a 0℃ low temperature cold bath, and drop 250mL of sodium hydroxide solution (2M) while stirring. The reaction mixture was extracted three times with 200 mL of ethyl acetate, the organic phase was retained, dried with anhydrous sodium sulfate, the solvent was removed under reduced pressure, and 6.2 g of light yellow oily liquid (IV-1) was obtained after column purification. The reaction yield was 84%, and the ee value was 96% as determined by HPLC analysis. [α] D 25 = +35.6 (c = 1.00 in CHCl 3 ), 1 HNMR (400MHz, CDCl 3)δ:7.28–7.11(m,1H),6.99–6.84(m,1H),6.88–6.82(m,1H),4.39(t,J=7.9Hz,1H),3.17–3.13(m,1H),3.07–3.01(m,1H),2.29–2.21(m,1H),2.17(s,1H),1.93–1.80(m,2H),1.65–1.58(m,1H). Its H NMR spectrum data are consistent with the literature (J.Am.Chem.Soc.2019,141,14083-14088.).
[0086] Embodiment 40
[0087]
[0088] The compound of formula IV-1 (1.83 g, 10 mmol), the compound of formula V1 (1.99 g, 10 mmol) and 20 mL of ethanol were added to a 50 mL three-necked flask, stirred evenly, and the system temperature was kept below 30 ° C. Triethylamine (1.53 mL, 11 mmol) was added dropwise, and after the addition was completed, the reaction was carried out at 50 ° C for 2 hours. After the reaction was completed, it was directly dried and purified by column (petroleum ether: ethyl acetate = 2:1) to obtain 2.76 g of larotrectinib intermediate VI-1, with a yield of 80%. The ee value was measured by HPLC analysis and was 96%. Characterization data of compound VI-1: [α] D 25 = -27.0 (c = 1.00 in CHCl 3 ). Enantiomers were determined by HPLC, and the chromatographic conditions were: ChiralcelIA column, 250nm, 30°C, mobile phase n-hexane:i-PrOH=90:10; flow rate 1.0mL / min; t R (minor)=26.6min,t R (major) = 28.9min.
[0089] Major: 1 H NMR (600 MHz, DMSO-d 6 )δ8.71(d,J=7.8Hz,1H),8.42(s,1H),7.16–7.08(m,1H),6.95–6.89(m,2H),6.68(d,J=7.8Hz,1H),5 .48(d,J=5.6Hz,1H),3.98–3.92(m,1H),3.58(q,J=8.1Hz,1H),2.38–2.32(m,1H),2.01–1.83(m,3H). 13 C NMR (151 MHz, DMSO-d6 ) δ 158.06 (d, J = 240.1 Hz), 156.16, 155.76 (d, J = 240.8 Hz), 142.85, 141.53, 136.99, 132.04 (dd, J = 15.9, 7.1 Hz), 119.34, 116.69 (dd, J = 24.6, 8.6 Hz), 114.68 (dd, J = 24.2, 8.7 Hz), 114.07 (dd, J = 25.1, 4.5 Hz), 100.49, 56.39, 48.18, 32.65, 23.13. 19 F NMR (565 MHz, DMSO-d 6 ) δ -118.93 (ddd, J = 16.9, 12.7, 8.4 Hz), -123.75 (dd, J = 15.2, 6.7 Hz).
[0090] Minor: 1 H NMR (600 MHz, DMSO-d 6 ) δ 8.54 (d, J = 7.8 Hz, 1H), 8.51 (s, 1H), 7.26–7.22 (m, 1H), 7.11–7.08 (m, 1H), 6.98–6.96 (m, 1H), 6.12 (d, J = 7.8 Hz, 1H), 5.26 (d, J = 7.4 Hz, 1H), 3.98–3.92 (m, 1H), 3.77–3.73 (m, 1H), 2.48–2.43 (m, 1H), 2.01–1.83 (m, 3H). 13 C NMR (151 MHz, DMSO-d 6 ) δ 158.30 (d, J = 241.5 Hz), 156.40, 155.38 (d, J = 236.4 Hz), 143.32, 141.79, 136.94, 130.62 (dd, J = 15.8, 6.8 Hz), 119.60, 117.51 (dd, J = 24.1, 8.7 Hz), 115.77 (dd, J = 24.1, 8.6 Hz), 113.89 (dd, J = 30.0, 4.2 Hz), 100.20, 56.46, 48.38, 34.04, 22.00. 19 F NMR (565 MHz, DMSO-d 6 ) δ -117.66 (ddd, J = 16.4, 12.0, 7.9 Hz), -122.75– -122.91 (m).
[0091] Example 41 (Scale-up, S / C = 200000)
[0092]
[0093] Under argon atmosphere, [Ir(COD)Cl] 2 (1.4mg, 0.002mol) and chiral ligand (S,S,R)-f-phamidol-L3 (2.4mg, 0.0042mmol) were dissolved in 10mL isopropanol and stirred at room temperature for 2 hours to obtain an orange clear solution. 50uL of the orange solution was taken with a microsyringe and added to a mixed system of intermediate (It) (1.10g, 4mmol), isopropanol (2mL) and potassium methoxide (14mg, 0.2mmol). The reaction system was placed in an autoclave, and the gas in the autoclave was replaced with hydrogen three times. Finally, 50atm hydrogen was filled and reacted at 25°C for 16 hours. After the reaction was completed, the gas in the autoclave was slowly released, the alkali was filtered off with silica gel, rinsed with DCM, and concentrated under reduced pressure to obtain 1.11g of light yellow oily liquid, i.e., hydrogenation product (II-t), with a yield of 99%. The ee value was measured to be >99% by HPLC analysis. [α] D 25 = +18.7 (c = 1.00 in CHCl 3 ).The enantiomeric excess was determined by HPLC on Chiralcel OD-H column,210nm,30℃,n-hexane:i-PrOH=95:5; flow rate 1.0mL / min; t R (minor)=20.8min,t R (major) = 25.1min. 1 H NMR (400 MHz, CDCl 3 )δ7.34–7.30(m,4H),7.27–7.23(m,1H),4.64–4.61(m,2H),3.07–3.06(m,2 H),2.53(br,1H),1.83–1.65(m,2H),1.48–1.42(m,12H),1.32–1.26(m,1H). 13 C NMR (151 MHz, CDCl 3 )δ156.00,144.78,128.31,127.34,125.77,79.00,74.17,40.23,38.55,29.83,28.34,22.82.
[0094] Embodiment 42
[0095]
[0096] Weigh 1.11g of chiral alcohol intermediate (II-t, 4mmol), add 20mL of dichloromethane to dissolve, then drop 0.84mL of triethylamine (6mmol), place the reaction system in a 0℃ low temperature cold bath, slowly drop 0.40mL of methanesulfonyl chloride (5.2mmol) while stirring, continue to react at 0℃ for 3h after the dropwise addition, add 80mL of ethyl acetate to dilute, wash twice with water, wash twice with saturated sodium bicarbonate, dry the organic phase with anhydrous sodium sulfate, and concentrate to obtain a yellow oily liquid. Then drop 1.04mL of methanesulfonic acid (16mmol) and 16mL of dichloromethane into the yellow oily liquid obtained above, stir at room temperature for 2h, place the reaction solution in a 0℃ low temperature cold bath after the reaction, then add 20mL of water, and drop sodium hydroxide solution (1M) while stirring until the pH is about 11. The reaction mixture was extracted with 150 mL of dichloromethane three times, the organic phase was retained, dried with anhydrous sodium sulfate, the solvent was removed under reduced pressure, and 509 mg of colorless oily liquid (IV-t) was obtained after column purification. The reaction yield was 79%, and the ee value was 98% as determined by HPLC analysis. [α] D 25 =-35.0(c=1.00in CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 )δ7.34–7.20(m,5H),3.55–3.53(m,1H),3.15–3.12(m,1H),2.70–2.69(m,1H),1.83–1.81(m,1H),1.76-1.74(m,1H),1.68(br,1H),1.62–1.60(m,1H),1.52–1.45(m,3H). Its H NMR spectrum data are consistent with the literature (Org.Lett.2017,16,4215-4218.).
[0097] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for preparing amino alcohols by asymmetric hydrogenation, characterized in that: The chemical reaction equation is as follows: Among them, R of the chemical formula (I) and (II) 1 represents a C1-C12 alkyl group, an aryl group, or an alkyl group or an aryl group substituted with a heteroatom, R 2 represents an amino protecting group, n represents 1 to 5 carbon atoms, and the * represents two configurations, R or S; The transition metal catalyst used is prepared by mixing a metal salt and a chiral ligand, wherein the metal salt is selected from a transition metal compound of ruthenium, rhodium, iridium or palladium, and the chiral ligand is selected from:
2. The method for preparing amino alcohols by asymmetric hydrogenation according to claim 1, characterized in that: R in the general chemical formula (I) and (II) 2 represents an amino protecting group selected from benzyloxycarbonyl, tert-butyloxycarbonyl, tert-methoxycarbonyl, allyloxycarbonyl, trimethylsilylethoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, phthaloyl, p-toluenesulfonyl, trifluoroacetyl, nitrobenzenesulfonyl, pivaloyl, benzoyl, trityl, 2,4-dimethoxybenzyl, p-methoxybenzyl or benzyl.
3. The method for preparing amino alcohols by asymmetric hydrogenation according to claim 1, characterized in that: The solvent used for asymmetric hydrogenation is one of methanol, ethanol, isopropanol, tetrahydrofuran, dichloromethane, ethyl acetate, n-hexane, dichloromethane, 1,2-dichloroethane, toluene, xylene, 1,4-dioxane, methyl tert-butyl ether or a mixture in any proportion.
4. The method for preparing amino alcohols by asymmetric hydrogenation according to claim 1, characterized in that: The base used for asymmetric hydrogenation is one or a mixture of any proportion of potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, potassium methoxide; the molar ratio of the chemical formula (I) to the catalyst is 5mmol:0.01-1nmol; the reaction temperature of the asymmetric hydrogenation is 20-80 degrees Celsius, and the pressure of the asymmetric hydrogenation is 1-10Mpa.
5. The method for preparing amino alcohols by asymmetric hydrogenation according to claim 1, characterized in that: The transition metal catalyst is generated by mixing a metal salt and a chiral ligand, wherein the metal salt is [Ir(COD)Cl]2 and the chiral ligand is: and its enantiomer L10.
6. A method for asymmetric synthesis of chiral pyrrolidine and piperidine compounds, characterized in that: The synthetic route is as follows: Wherein, the chiral amino alcohol compound (II) is prepared by the method according to any one of claims 1 to 5, wherein n in the compounds (I) and (II) is 3 or 4, and R 1 represents a C1-C12 alkyl group, an aryl group, or an alkyl group or an aryl group substituted with a heteroatom, R 2 represents an amino protecting group, and X is a leaving group selected from a halogen, a sulfonate group or a phosphate group.
7. The method according to claim 6, characterized in that The alcoholic hydroxyl group of the chiral amino alcohol compound (II) is converted by reaction with a suitable reagent to obtain group X, i.e., compound (III), wherein group X is one of chlorine, bromine, iodine, methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate or nitrosulfonate.
8. The method according to claim 6, characterized in that Under appropriate conditions, the intermediate (III) reacts with a suitable reagent to remove the amino protecting group R 2 , R 2 When it is tert-butyloxycarbonyl, the reagent for removing the amino protecting group is hydrochloric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid or methanesulfonic acid, and an intramolecular nucleophilic ring-closing reaction occurs under alkaline conditions to obtain optically pure chiral pyrrolidine and piperidine compounds.
9. The method according to claim 6, when R 1 When represents 3-pyridyl, the method can be applied to the asymmetric synthesis of nicotine, characterized in that The synthetic route is as follows: Wherein, the "*" in formula II-b, III-b, IV-b and Vb indicates that it contains two configurations, R and S. The synthesis comprises the following steps: 1) Dissolve the intermediate Ib in a suitable solvent, add a chiral catalyst and a suitable base, the molar ratio of the intermediate Ib to the catalyst is 2mmol:0.01-1nmol, replace the gas in the reactor with hydrogen three times, and finally fill with 2-8Mpa hydrogen, react at 20-80°C for 2-60 hours, slowly release the gas in the reactor, spin dry, and purify by silica gel column chromatography to obtain a chiral hydrogenation product II-b; 2) The chiral alcohol product II-b is activated by SOCl2, MsCl, and TsCl to form an intermediate III-b, where LG is a halogen or sulfonate leaving group; 3) The intermediate III-b is reacted with one of hydrochloric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid, and methanesulfonic acid or a mixture in any proportion to remove the amino protecting group, and then an intramolecular nucleophilic ring-closing reaction occurs under alkaline conditions. After the reaction is completed, it is extracted with ethyl acetate, and the organic phase is collected and concentrated to obtain a chiral tetrahydropyrrole compound IV-b; 4) Under heating conditions, the intermediate IV-b is added to formic acid and paraformaldehyde solution to react for 5 hours, the reaction is cooled to room temperature, potassium carbonate is added until the reaction solution becomes alkaline, and ethyl acetate is extracted and distilled under reduced pressure to obtain the nicotine product.
10. The method according to claim 6, when R 1 When represents 2,5-difluorophenyl, the method can be applied to the asymmetric synthesis of larotrectinib intermediates, characterized in that The synthetic route is as follows: Specifically, the method comprises the following steps: 1) in the presence of a chiral catalyst, asymmetric catalytic hydrogenation reduction is performed on compound Il using the preparation method described in any one of claims 1 to 5 to obtain a chiral alcohol compound II-1; 2) chiral alcohol II-1 is activated, the Boc protecting group is removed, and intramolecular cyclization is performed under the action of a base to obtain an important intermediate IV-1, namely (R)-2-(2,5-difluorophenyl)pyrrolidine; 3) a compound of formula IV-1 and a compound of formula V1 undergo a substitution reaction to obtain a larotrectinib intermediate VI-1.
Citation Information
Patent Citations
Iron(II) catalysts containing diimino-diphosphine tetradentate ligands and their synthesis
CA2642563A1
Chiral tridentate nitrogen-phosphine-oxygen ligands and application of related ligands in asymmetric catalytic reactions
CN105732725A
Method for efficiently synthesizing chiral 1,2-amino alcohol by catalyzing alpha-aminoketone through Ir / f-amphox
CN107021884A
Fused ring heteroaryl compounds and their use as trk inhibitors
CN107207514A
Synthesis process of chiral pyrrolidine and intermediates
CN108101820A
